Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Brunswick Corporation (BC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Brunswick Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Brunswick Corporation trades at $77.91 (market cap $5.06B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.9× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.26% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BC | |
|---|---|---|
Market Cap | $39.89B | $5.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $89.22 |
52-Week Low | $278.09 | $56.64 |
Enterprise Value | $38.15B | $7.22B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BC trades at $77.9, down 0.12% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a high P/E of 73.92 and negative net income margin of -2.47%, though revenue remains stable near $5.4 billion. Recent news highlights operational updates and expansion milestones, including Freedom Boat Club's 450th location opening (GlobeNewsWire, June 23, 2026).
Outlook is cautiously optimistic given the 71% buy rating from analysts and an $86.40 consensus price target, but risks include persistent negative profitability and high debt levels. The upcoming Q2 2026 earnings report on July 30, 2026 (GlobeNewsWire, July 9, 2026) will be critical for confirming turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
